HPC
GANX icon

HM Payson & Co’s Gain Therapeutics GANX Stock Holding History

HM Payson & Co’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$3.77K – 1012
2024
Q1 		$3.77K Hold
1,000
– – ﹤0.01% 882
2023
Q4 		$3.27K Hold
1,000
– – ﹤0.01% 888
2023
Q3 		$3.28K Hold
1,000
– – ﹤0.01% 903
2023
Q2 		$4.48K Buy
+1,000
New +$4.88K ﹤0.01% 861

Other funds holding GANX

TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $847M AUM 29.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HM Payson & Co's GANX Position: Q2 2024 in Review

HM Payson & Co sold out of Gain Therapeutics (GANX) in Q2 2024, closing a stake of 1,000 shares — an estimated $3.77K sold.

HM Payson & Co first reported a position in GANX in Q2 2023 and held it in 4 quarters. The position peaked at $4.48K in Q2 2023. 28 funds tracked by Wall St. Rank hold GANX as of Q2 2024.

  • HM Payson & Co reported no remaining Gain Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HM Payson & Co sold 1,000 Gain Therapeutics shares in Q2 2024, an estimated $3.77K.
  • HM Payson & Co first reported a position in Gain Therapeutics in Q2 2023 and held it in 4 quarters.
  • HM Payson & Co's Gain Therapeutics position peaked at $4.48K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2024.

Based on HM Payson & Co's 13F filing for Q2 2024, filed 13 Aug 2024.